TOP > 外国特許検索 > INNOVATIVE PRODUCTION TECHNIQUE FOR ANTIBODY-ENZYME

INNOVATIVE PRODUCTION TECHNIQUE FOR ANTIBODY-ENZYME

外国特許コード F210010492
整理番号 J1039-01WO
掲載日 2021年7月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP028435
国際公開番号 WO 2021015237
国際出願日 令和2年7月22日(2020.7.22)
国際公開日 令和3年1月28日(2021.1.28)
優先権データ
  • 特願2019-136403 (2019.7.24) JP
発明の名称 (英語) INNOVATIVE PRODUCTION TECHNIQUE FOR ANTIBODY-ENZYME
発明の概要(英語) A method for producing an antibody κ-type light chain having enzyme activity or improved enzyme activity includes: a modification step for modifying a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is a proline residue so that the proline residue is deleted or substituted to obtain a polynucleotide encoding an antibody κ-type light chain in which the variable region is a polypeptide comprising an amino acid sequence in which the 95th amino acid residue from the N-terminal of the variable region by the Kabat classification is deleted or an amino acid residue other than a proline residue; and an expression step for expressing the antibody κ-type light chain having enzyme activity by an intracellular or extracellular expression system using an expression vector including the polynucleotide encoding an antibody κ-type light chain from after the modification step.
従来技術、競合技術の概要(英語) BACKGROUND ART
The antibody is composed of a heavy chain (H chain: Heavy chain) and a light chain (L chain: Light chain). The heavy and light chains are composed of a variable region (VR: Variable Region) and a constant region (CR: Constant Region), where the variable region has a hypervariable region (CDR: Complimentarity Determining Region). Furthermore, the light chains of antibodies are classified into kappa and lambda forms.
Recently, enzyme-like active antibodies, i.e., antibody enzymes, have attracted attention. Antibody enzymes have both high molecular recognition ability and enzymatic activity of antibodies, and therefore are expected to be used in many respects such as the medical, chemical, food industry, and the like. In particular, an antibody enzyme that has high specificity for a target molecule and that can exhibit damage to the target molecule by its enzymatic activity is expected to be an excellent anti-cancer agent with few side effects. Human antibody enzymes, in particular, are expected to have fewer side effects when administered to the human body, so domestic and domestic pharmaceutical companies await to develop useful human antibody enzymes.
The inventors have previously performed various inventive studies on antibody enzymes (see, for example, Patent Document 1 ~ 4 and the like).
In order to clinically use the antibody enzyme as a medicament, it is important that the antibody enzyme having sufficient activity can be stably mass-produced. However, many antibody enzymes suffer from insufficient enzymatic activity and when artificially synthesized by intracellular or extracellular expression systems using recombinant techniques, they are not stable in performance and have large lot-to-lot differences.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA Taizo
  • HIFUMI Emi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close